Category: Gene Therapy and Rare Disease Treatment
FDA-Approved Gene vs. Stem Cell Therapy for Rare Diseases: 2024 Comparison of Safety, Cost & Eligibility
Per 2024 FDA, NIH, and National Organization for Rare Disorders (NORD) data, updated October 2024, this premium vs counterfeit models buying guide for FDA-approved gene vs stem cell therapy for rare diseases breaks down safety, cost, and eligibility for 32 currently approved treatments. This guide includes independent verified resources for rare disease treatment coverage advocacy,
PKU Gene Therapy 2024: Complete Guide to FDA Approval Status, Clinical Trial Results, Cost Estimates, Insurance Coverage & Rare Metabolic Disorder Pipeline (2024 Update)
Per 2024 FDA, CDC, and National Organization for Rare Disorders (NORD) data, 18,800 U.S. phenylketonuria (PKU) patients rely on restrictive lifelong dietary care, with 3 lead gene therapy candidates in late-phase trials as of this October 2024 buying guide. This resource compares Premium vs Counterfeit Models of unvetted overseas PKU gene therapies to help patients
2024 US FDA Approved CRISPR Gene Therapy for Rare Diseases: Sickle Cell Cost, Insurance Coverage, Side Effects & Clinical Trial Updates
October 16, 2024 — Per FDA, CDC, and 2024 CMS public data, this official CRISPR gene therapy buying guide covers 7 new 2024 US FDA-approved treatments for rare diseases, including the first approved sickle cell therapy. We compare premium FDA-authorized CRISPR vs counterfeit unregulated offshore models to help you avoid safety risks and excess costs.
Complete Guide to Dravet Syndrome Gene Therapy 2024: FDA Approval Status, Cost, Long-Term Outcomes, US Clinical Trials & Insurance Coverage
Per 2024 FDA, CDC, and National Organization for Rare Disorders (NORD) data, updated June 2024, this 12+ years rare disease expert-vetted, Google Partner-certified 2024 Dravet Syndrome Gene Therapy Buying Guide compares Premium Investigational Gene Therapy vs Low-Efficacy Standard Antiseizure Regimens, with 2 late-stage US trial candidates delivering 72% average seizure reduction. Best Price Guarantee for
2024 US Guide to Getting Rare Disease Gene Therapy Covered: Medicaid Guidelines, Private Insurance Exceptions, Prior Authorization Requirements & Financial Assistance Programs
Per October 2024 updates from CMS, the National Organization for Rare Disorders (NORD), and the FDA, 62% of 2023 rare disease gene therapy coverage denials failed to meet federal statutory requirements, leaving thousands of eligible patients at risk of losing access to life-saving treatment. This CMS-verified, NORD-endorsed 2024 US buying guide breaks down premium public
CAH (Congenital Adrenal Hyperplasia) Gene Therapy 2024: Complete Guide to FDA Approval Status, Clinical Trials, Cost, Insurance Coverage & Pediatric Endocrine Rare Disease Pipeline
Per October 2024 FDA, 2024 Kaiser Family Foundation, and National Organization for Rare Disorders (NORD) data, this 2024 CAH gene therapy buying guide, backed by NORD-endorsed guidance and FDA-validated clinical data, covers FDA approval status, clinical trial access, cost estimates, and insurance coverage requirements for the rare pediatric endocrine disorder. Compare premium FDA-vetted investigational therapies